Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
3.540 USD | -4.32% | -4.07% | -16.11% |
Financials (USD)
Sales 2023 * | 0 M | Sales 2024 * | 37 M | Capitalization | 203 M |
---|---|---|---|---|---|
Net income 2023 * | -51 M | Net income 2024 * | -42 M | EV / Sales 2023 * | -591x |
Net cash position 2023 * | 55 M | Net cash position 2024 * | 43 M | EV / Sales 2024 * | 4,34x |
P/E ratio 2023 * | -3,62x | P/E ratio 2024 * | -5,19x | Employees | - |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.11% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -4.32% | ||
1 week | -4.07% | ||
Current month | -4.32% | ||
1 month | -10.38% | ||
3 months | -9.23% | ||
6 months | -18.24% | ||
Current year | -16.11% |
1 week
3.52
3.79

1 month
3.52
4.18

Current year
3.20
6.09

1 year
2.71
6.09

3 years
2.65
18.80

5 years
2.16
18.80

10 years
0.86
52.00

Managers | Title | Age | Since |
---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 47 | 2022 |
Mathew David
DFI | Director of Finance/CFO | 46 | 2020 |
Chief Tech/Sci/R&D Officer | 44 | 2018 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Todisco
BRD | Director/Board Member | 47 | 2022 |
Myron Kaplan
CHM | Chairman | 78 | 2017 |
Steven Lefkowitz
BRD | Director/Board Member | 67 | 2017 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 293,477 M$ | +10.95% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-10-02 | 3.540 | -4.32% | 482,871 |
23-09-29 | 3.700 | +0.27% | 530,016 |
23-09-28 | 3.690 | +0.54% | 506,838 |
23-09-27 | 3.670 | +0.27% | 342,452 |
23-09-26 | 3.660 | -0.81% | 372,237 |
Delayed Quote Nasdaq, October 02, 2023 at 04:00 pm EDT
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2023-10-26
- Annual General Meeting
Trading Rating :
Investor Rating :
ESG Refinitiv :
D
Sell
Buy

Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.700USD
Average target price
13.75USD
Spread / Average Target
+271.62%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-16.11% | 203 M $ | |
-63.40% | 128 M $ | |
+47.83% | 277 M $ | |
+145.28% | 110 M $ | |
+51.79% | 78 M $ | |
+68.79% | 849 M $ | |
+67.38% | 2 541 M $ | |
+55.64% | 190 M $ | |
+19.56% | 5 015 M $ | |
+32.52% | 4 011 M $ |